Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-043121

Chief Executive Officer sold 8,342 shares at $3.56 ($29,710)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Brainard Diana Chief Executive Officer 2023-07-19 Sale 10b5-1 −8,342 $3.56 $29,710 907,299 D: show line 1 in the form
Open-market sales · 8,342 sh · avg $3.56 · $29,710
Loading xslF345X05/doc4.xml…